Determinants of efficacy and safety in epicutaneous allergen immunotherapy: Summary of three clinical trials

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 6, 2015, Pages 707-710

  Senti, G ^a   Von Moos, S ^b   Tay, F ^a   Graf, N ^c   Johansen, P ^d   Kündig, Tomas M ^d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Graf Biostatistics   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

allergen specific antibodies; allergic rhinoconjunctivitis; epicutaneous allergen specific immunotherapy; needle free immunisation; patch immunisation

Indexed keywords

GRASS POLLEN EXTRACT; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PLANT EXTRACT;

ABRASION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECZEMA; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLLEN ALLERGY; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; T LYMPHOCYTE; THERAPY EFFECT; TRANSDERMAL PATCH; VISUAL ANALOG SCALE; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; MIDDLE AGED; POACEAE; POLLEN; PROCEDURES; RHINITIS, ALLERGIC; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PLANT EXTRACTS; POACEAE; POLLEN; RHINITIS, ALLERGIC; RHINITIS, ALLERGIC, SEASONAL; TRANSDERMAL PATCH; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929963057     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12600     Document Type: Article

References (15)

1. Ring J, Gutermuth J,. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy 2011; 66: 713-724.
2. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS,. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
3. Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP,. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013; 132: 353-360.
4. Igyarto BZ, Kaplan DH,. Antigen presentation by Langerhans cells. Curr Opin Immunol 2013; 25: 115-119.
5. von Moos S, Johansen P, Tay F, Graf N, Kundig TM, Senti G,. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. J Allergy Clin Immunol 2014; 134: 965-967.
6. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al., Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129: 128-135.
7. Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T, et al., Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124: 997-1002.
8. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M, et al., Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507-514.
9. James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, et al., Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127: 509-516.
10. von Moos S, Johansen P, Waeckerle-Men Y, Mohanan D, Senti G, Haffner A, et al., The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 2012; 67: 638-646.
11. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al., Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
12. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al., Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198-1208.
13. Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA,. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 2010; 148: 266-282.
14. Scheiblhofer S, Thalhamer J, Weiss R,. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Expert Opin Drug Deliv 2013; 10: 761-773.
15. Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, et al., Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127: 860-864.